Insulin Treatment in Type 2 Diabetes

Improved diabetes medication convenience and satisfaction in persons with type 2 diabetes after switching to insulin glargine 300 U/mL: results of the observational OPTIN-D study
Thomas H Wieringa, Maartje de Wit, Jos WR Twisk, Frank J Snoek

BMJ Open Diabetes Research and Care Oct 2018, 6 (1) e000548; DOI: 10.1136/bmjdrc-2018-000548
Impact of a structured patient support program on adherence and persistence in basal insulin therapy for type 2 diabetes
Fang Liz Zhou, Jason Yeaw, Swapna U Karkare, Mitch DeKoven, Paulos Berhanu, Timothy Reid

BMJ Open Diabetes Research and Care Dec 2018, 6 (1) e000593; DOI: 10.1136/bmjdrc-2018-000593
Determining starting basal rates of insulin infusion for insulin pump users: a comparison between methods
Nelson Chow, Daniel Shearer, Hamish G Tildesley, Jessica Aydin Plaa, Betty Pottinger, Monika Pawlowska, Adam White, Anne Priestman, Stuart A Ross, Hugh D Tildesley

BMJ Open Diabetes Research and Care Mar 2016, 4 (1) e000145; DOI: 10.1136/bmjdrc-2015-000145
BeAM value: an indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes mellitus receiving basal insulin
Ariel Zisman, Francienid Morales, John Stewart, Andreas Stuhr, Aleksandra Vlajnic, Rong Zhou

BMJ Open Diabetes Research and Care Apr 2016, 4 (1) e000171; DOI: 10.1136/bmjdrc-2015-000171
Sitagliptin versus mitiglinide switched from mealtime dosing of a rapid-acting insulin analog in patients with type 2 diabetes: a randomized, parallel-group study
Yumie Takeshita, Toshinari Takamura, Yuki Kita, Akiko Takazakura, Ken-ichiro Kato, Yuki Isobe, Shuichi Kaneko

BMJ Open Diabetes Research and Care Aug 2015, 3 (1) e000122; DOI: 10.1136/bmjdrc-2015-000122

Log in using your username and password

Main menu

Log in using your username and password

You are here

Insulin Treatment in Type 2 Diabetes